Gilead Sciences

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five...

The Past Week, In A Nutshell What Happened: Last week ended negative alongside mixed messaging on stimulus. Remember This: “Markets have come a long way since the March lows, but we believe there may be more room for stocks to run,” said Jeff Buchbinder, Equity Strategist for LPL...

Drum roll, please. Will this be another weekend where investors wait for late-breaking news of a fiscal stimulus deal? Does it really matter to the market anymore?  After so many weeks, there’s a sense of exhaustion hanging around the trading arena. Our collective attention span has...

Everyone complains about the weather, but no one does anything about it, Mark Twain once quipped. That’s also partly true with COVID-19, at least the part about everyone complaining. The difference is, a lot of people are trying to do something about it, which brings us to coming earnings...

Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion. Per the Wall Street Journal, Immunomedics — a biotech known for breast-cancer treatment Trodelvy — was initially a...

Benzinga has examined the prospects for many investor favorite stocks over the past week. This past week's bullish calls included automaker and retail giants. Fast food and semiconductor stocks were among the bearish calls. The stock market returned to record highs last week as a remarkably...

Benzinga has examined the prospects for many investor favorite stocks over the past week. This week's bullish calls included the iPhone maker and the king of e-commerce. A coronavirus play and the electric vehicle leader were among the bearish calls. Fears of a pandemic resurgence and other...

This weekend's Barron's cover story shows how the race for a COVID-19 vaccine could affect investors. Other featured articles look at stocks involved in the race for 5G and some value stocks that are worth a look now. Also, the prospects for an online retailer, a networking stock, video...

This weekend's Barron's cover story examines how consumer spending will affect the economic recovery. Other featured articles offer energy stock and bond picks, as well as retail stocks poised to thrive. Also, the prospects for Warren Buffett's empire, a used car purveyor and an iconic...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured a top biotech, an online payment company and an energy infrastructure giant. Bearish calls included a leading coffee chain, REITs and a hotel operator in the news. Volatility came...

The preliminary success of a drug designed to combat idiopathic pulmonary fibrosis could give Galapagos NV (ADR) (NASDAQ: GLPG) a 10-percent boost, according to Morgan Stanley. A 23-person study of the drug GLPG1690, an autotaxin inhibitor, found that patients had better lung function than those...

This weekend's Barron's features a look at how Canadian stocks have fared and how to play the trends. Other featured articles discuss one particular Canadian stock that has caught the eye of short sellers and a rising software star benefiting from the ecommerce arms race. The...

Featured stories this weekend in Barron's ponder the prospects for public sports team owner and a global health services company. The prospects for a commercial property owner are also examined in the wake of the Brexit vote. This week's cover story takes a closer look at the...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...